Podcasts about Bioethics

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What the heck is going on with health and science in Washington DC these days?  Nothing good, bioethicist Art Caplan assures you.

America Out Loud PULSE with Dr. Randall Bock – Utilitarian bioethics* now dominates universities. Its premise—maximizing happiness for the greatest number—places power in the hands of whoever defines “happiness.” The hearings turned personal. Malone described the culture of censorship as a form of arrested development. “This failure of empathy… that is what we are dealing with.”

America Out Loud PULSE with Dr. Randall Bock – Utilitarian bioethics* now dominates universities. Its premise—maximizing happiness for the greatest number—places power in the hands of whoever defines “happiness.” The hearings turned personal. Malone described the culture of censorship as a form of arrested development. “This failure of empathy… that is what we are dealing with.”

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Prior to coming to NYU, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. He has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics; the University of Pittsburgh; and Columbia University. He received his PhD from Columbia University. Dr. Caplan is the author or editor of 35 books and more than 880 papers in peer reviewed journals. His books include Vaccination Ethics and Policy, with Jason Schwartz, and, Getting to Good: Research Integrity in Biomedicine, with Barbara Redman. He has served on a number of national and international committees including as the chair of the National Cancer Institute Biobanking Ethics Working Group; chair of the Advisory Committee to the United Nations on Human Cloning; and chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses, the Special Advisory committee to the International Olympic Committee on Genetics and Gene therapy, the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects, the Wellcome Trust Advisory Panel on Research in Humanitarian Crises, and as the co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to Fertility & Sterility Roundtable! Each month, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility & Sterility.  This month, we welcome Dr. Lydia Hughes and Dr. Eric Widra to discuss the ethics of egg-sharing, or "split-cycles" for fertility preservation. This is where an egg donor freezes their eggs for their own future use for reduced or no cost in exchange for donating a portion of the cohort. Dr. Hughes is a second-year REI fellow at Northwestern University in Chicago, where she also completed her residency in Obstetrics and Gynecology. She earned her medical degree from the University of Alabama at Birmingham. Dr. Hughes's clinical and academic interests include reproductive ethics, PCOS, and ovarian aging.  Dr. Widra currently serves as Executive Senior Medical officer and Vice President, Development for Shady Grove Fertility and US Fertility, respectively.  He was formerly Chief Medical Officer of SG Fertility, and Associate Director of the Combined Federal Fellowship in Reproductive Endocrinology and Infertility, operated through the NIH, Walter Reed National Military Medical Center and SG Fertility. View Fertility and Sterility at https://www.fertstert.org/    

In this episode of PRIM&R's podcast, "Research Ethics Reimagined," we explore the intersection of artificial intelligence, trust, and bioethics with Dr. Vardit Ravitsky, President and CEO of the Hastings Center for Bioethics. Dr. Ravitsky discusses the rapid implementation of AI in healthcare and biomedical research, strategies for combating misinformation, and maintaining organizational values during challenging political times. She also shares practical advice for emerging professionals in bioethics and biomedical research.

Dr. Amy Adamczyk joins host Dr. Mike Chupp and CMDA's Vice President of Advocacy and Bioethics, Dr. Brick Lantz, to explore why views on abortion vary so widely across nations. A sociology professor at John Jay College and author of Fetal Positions, Dr. Adamczyk draws on decades of global research to show how culture, religion, economics, and policy shape public opinion. CMDA holds firmly to the biblical conviction that every life is made in God's image and worthy of protection, and this conversation seeks perspective on eye-opening global data, offering insights that can sharpen our convictions and encourage Christian healthcare professionals in our witness.

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

How New Zealand media covered Covid-19 made the pandemic seem like a competition or a war the country was winning. That's according to a University of Otago study. Bioethics researchers analysed more than a thousand news articles .. and the result is fascinating. Lead author and PHD candidate Emma Anderson talks to Jesse.

In this conversation, Dr. Wylin D. Wilson discusses the concept of womanist bioethics, its historical context, and the need for a more inclusive approach to bioethics that addresses the experiences of marginalized populations, particularly women of color. The discussion highlights the shortcomings of mainstream bioethics and the importance of expanding narratives to include diverse voices in healthcare and ethical considerations. In this conversation, Wylin D. Wilson and David Bryan explore the complex intersections of race, genetics, healthcare, and faith. They discuss the role of public health in addressing racism as a social determinant of health, the historical significance of the Black church in public health activism, and the broader implications of womanist bioethics. The conversation emphasizes the importance of awareness, advocacy, and the interconnectedness of all individuals in addressing health disparities and fostering community well-being.Dr. Wylin D. Wilson is Assistant Professor of Theological Ethics at Duke Divinity School, where she teaches within the Theology, Medicine and Culture Initiative.  Her teaching and research are at the intersection of Bioethics, Gender, and Theology. She is former Teaching Faculty at Harvard Medical School Center for Bioethics, she served as a Senior Fellow at the Harvard Divinity School Center for the Study of World Religions, and Visiting Lecturer in Harvard Divinity School Women's Studies in Religion Program.  She is also former Associate Director of Education for the Tuskegee University National Center for Bioethics in Research and Health Care and former faculty member of the Tuskegee University College of Agriculture, Environment and Nutrition Sciences. She is currently Principle Investigator for the Bioethics and Black Church: Addressing Racial Inequalities and Black Women's Health in North Carolina research project which examines the potential of the Black Church as a resource in addressing the Black maternal health crisis in the U.S. Dr. Wilson earned her Ph.D. in Religion, Ethics and Society from Emory University; her M.S. in Agricultural, Resource, and Managerial Economics from Cornell University; and her M.Div. from the Interdenominational Theological Center.  She is a member of the Society for the Study of Black Religion, the American Society for Bioethics and Humanities, the American Academy of Religion, and the Center for Reconciliation Advisory Board at Duke Divinity School. Dr. Wilson's publications include: “‘This is My Body': Faith Communities as Sites of Transfiguring Vulnerability” in Bioenhancement and the Vulnerable Body: A Theological Engagement (Baylor University Press, 2023); her first book, Economic Ethics and the Black Church (Palgrave Macmillan, 2017) and her second book, Womanist Bioethics: Social Justice, Spirituality and Black Women's Health (New York University Press).https://wylindwilson.com/linkedin.com/in/wylin-dassie-wilson-55bb7a47

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this powerful episode of Cultural Catalysts, we sit down with the Executive Director of the Center for Bioethics and Culture to explore the ethical questions surrounding gender transition medicine. Our guest, a former reproductive physiologist and perinatal nurse, shares her remarkable journey from asking critical questions about technologies to leading a global educational nonprofit. She discusses the center's groundbreaking documentary trilogy, "Transmission," "Detransition Diaries," and "The Lost Boys", which amplifies the voices of detransitioners and medical experts concerned about irreversible medical interventions for children. Join us for this thought-provoking conversation about parental rights, the medical risks of gender interventions, and the changing cultural and political landscape surrounding these issues. This episode offers valuable insights for parents, medical professionals, and anyone concerned about bioethical questions in today's complex world. Connect with Kris Vallotton: Website: https://www.krisvallotton.com/ Facebook: https://www.facebook.com/kvministries/ Instagram: https://www.instagram.com/kvministries/ X: https://x.com/kvministries Additional Resources by Kris Vallotton: https://shop.bethel.com/collections/kris-vallotton About Kris Vallotton: Kris Vallotton is the Senior Associate Leader of Bethel Church, Redding, and is the Co-Founder of Bethel School of Supernatural Ministry (BSSM) and Spiritual Intelligence Institute. He is also the Founder and President of Moral Revolution and a sought-after international conference speaker. Kris and his wife, Kathy, have trained, developed, and pastored prophetic teams and supernatural schools all over the world.

Interview: Dr Eric Topol (Part 1)We're joined by Dr Eric Topol—cardiologist, scientist, author, and global digital health leader. In part one, Eric shares his journey from clinician to digital health pioneer, his vision for “SuperAgers,” and why genomics and personalised medicine could redefine how long—and how well—we liveChatbots for PatientsWe discuss the Wall Street Journal's bold claim that chatbots could become part of the medical team. From spotting errors to translating lab results and reminding patients about medications, can they really serve as low-risk, always-on companion? Questions remain around accuracy, empathy, and whether they truly add value or just more noise.The Human Side of InteroperabilityInspired by Amy Gleason's LA Times op-ed, we look at the personal impact of fragmented health systems. Her daughter's care journey shows how disconnected records hinder outcomes—and how AI uncovered a hidden opportunity. Should we lean into more personal stories to communicate to a wider audience?Meta & Who Owns Your Health Data?A San Francisco jury found Meta guilty of illegally harvesting data from millions of Flo app users—menstrual cycles, ovulation, even pregnancy intentions. The ruling highlights urgent questions: Who really owns health data, and what rights do patients have when tech giants treat it like ad fuel?Patient Consent in the Age of AIConsent forms are broken—static, outdated, and unfit for the AI era. We unpack Y. Tony Yang's American Journal of Bioethics piece arguing for “dynamic consent,” accountability frameworks, and real patient understanding. Without rethinking consent, healthcare risks losing trust as AI tools grow more influentialBlack Box for Aged CareWhat if aged care had a “black box,” like aviation? Sensors, AI, and monitoring systems could flag risks before crises hit. A Pulse+IT blog argues for shifting from reactive to proactive care, but business models and adoption lag behind. We debate whether the sector can finally move from inquiry to preventionResources:Louise's LinkedIn poll on gen AI use for health research LinkDr Eric Topol's book SuperAgers LinkY. Tony Yang's American Journal of Bioethics Article on Patient Consent LinkAged Care's Black Box in Pulse+IT LinkAmy Gleason's parental perspective on the need for health data interoperability LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textDr. Michael Koren is joined by Dr. Ezekiel "Zeke" Emanuel, an oncologist, bioethicist, and former White House advisor. Dr. Emanuel talks about his enduring interest in bioethics and the importance of ethics in areas like clinical research. The two doctors also talk about shared experiences at Harvard Medical School and Dr. Emanuel's contributions to bioethics in healthcare and research over his career. They close Part 1 of this conversation with Dr. Emanuel laying out the disparities between US healthcare spending and health outcomes.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In this episode of Behind the Genes, we explore how Artificial Intelligence (AI) is being applied in genomics through cross-sector collaborations. Genomics England and InstaDeep are working together on AI and machine learning-related projects to accelerate cancer research and drive more personalised healthcare. Alongside these scientific advances, our guests also discuss the ethical, societal and policy challenges associated with the use of AI in genomics, including data privacy and genomic discrimination. Our guests ask what responsible deployment of AI in healthcare should look like and how the UK can lead by example. Our host, Francisco Azuaje, Director of Bioinformatics Genomics England is joined by Dr Rich Scott, Chief Executive Officer at Genomics England Karim Beguir - Chief Executive Officer at InstaDeep Harry Farmer – Senior Researcher at Ada Lovelace Institute If you enjoyed today's conversation, please like and share wherever you listen to your podcasts. And for more on AI in genomics, tune in to our earlier episode: Can Artificial Intelligence Accelerate the Impact of Genomics? "In terms of what AI's actually doing and what it's bringing, it's really just making possible things that we've been trying to do in genomics for some time, making these things easier and cheaper and in some cases viable. So really it's best to see it as an accelerant for genomic science; it doesn't present any brand-new ethical problems, instead what it's doing is taking some fairly old ethical challenges and making these things far more urgent."   You can download the transcript, or read it below.   Francisco: Welcome to Behind the Genes. [Music plays] Rich: The key is to deliver what we see at the heart of our mission which is bringing the potential of genomic healthcare to everyone.  We can only do that by working in partnership.  We bring our expertise and those unique capabilities.  It's about finding it in different ways, in different collaborations, that multiplier effect, and it's really exciting.  And I think the phase we're in at the moment in terms of the use of AI in genomics is we're still really early in that learning curve. [Music plays] Francisco: My name is Francisco Azuaje, and I am Director of Bioinformatics at Genomics England.  On today's episode I am joined by Karim Beguir, CEO of InstaDeep, a pioneering AI company, Harry Farmer, Senior Researcher at the Ada Lovelace Institute, and Rich Scott, CEO of Genomics England.  Today we will explore how Genomics England is collaborating with InstaDeep to harness the power of AI in genomic research.  We will also dive into the critical role of ethical considerations in the development and application of AI technologies for healthcare.  If you've enjoyed today's episode, please like, share on wherever you listen to your podcasts. [Music plays] Let's meet our guests. Karim: Hi Francisco, it's a pleasure to be here.  I am the Co-Founder and CEO of InstaDeep and the AI arm of BioNTech Group, and I'm also an AI Researcher. Harry: I'm Harry Farmer, I'm a Senior Researcher at the Ada Lovelace Institute, which is a think-tank that works on the ethical and the societal implications of AI, data and other emerging digital technologies, and it's a pleasure to be here. Rich: Hi, it's great to be here with such a great panel.  I'm Rich Scott, I'm the CEO of Genomics England. Francisco: Thank you all for joining us.  I am excited to explore this intersection of AI and genomics with all of you.  To our listeners, if you wish to hear more about AI in genomics, listen to our previous podcast episode, ‘Can Artificial Intelligence Accelerate the Impact of Genomics', which is linked in this podcast description. Let's set the stage with what is happening right now, Rich, there have been lots of exciting advances in AI and biomedical research but in genomics it's far more than just hype, can you walk us through some examples of how AI is actually impacting genomic healthcare research? Rich: Yeah, so, as you say, Francisco, it is a lot more than hype and it's really exciting.  I'd also say that we're just at the beginning of a real wave of change that's coming.  So while AI is already happening today and driving our thinking, really we're at the beginning of a process.  So when you think about how genomics could impact healthcare and people's health in general, what we're thinking about is genomics potentially playing a routine part in up to half of all healthcare encounters, we think, based on the sorts of differences it could make in different parts of our lives and our health journey.  There are so many different areas where AI, we expect, will help us on that journey.  So thinking about, for example, how we speed up the interpretation of genetic information through to its use and the simple presentation of how to use that in life, in routine healthcare, through to discovery of new biomarkers or classification that might help us identify the best treatment for people.  Where it's making a difference already today is actually all of those different points.  So, for example, there's some really exciting work we're doing jointly with Karim and team looking at how we might use classification of the DNA sequence of tumours to help identify what type of tumour - a tumour that we don't know where it's come from, so what we call a ‘cancer of unknown primary' - to help in that classification process.  We're also working with various different people who are interested in classification for treatment and trials, but there's also lots in between recognising patterns of genomic data together with other complex data.  So we've been doing a lot of work bringing image data together with genomic data and other health data so that you can begin to recognise patterns that we couldn't even dream of.  Doing that hand in hand with thinking about what patients and participants want and expect, how their data is used and how their information is held, bringing it all together and understanding how this works, the evidence that we need before we can decide that a particular approach is one that policymakers, people in healthcare want to use, is all part of the conversation. Francisco: Thank you, Rich, for speaking of cutting-edge AI applications and InstaDeep.  Karim, could you give us a glimpse into your work and particularly how your technologies are tackling some of the biggest challenges in genomic research? Karim: Absolutely, and I think what's exciting is we've heard from Rich and, you know, this is like the genomics expertise angle of things and I come from the AI world and so do most of the InstaDeep team.  And really what's fascinating is this intersection that is being extremely productive at the moment where technologies that have been developed for like multiple AI applications turn out to be extremely useful in understanding genomic sequences.  This is a little bit, our journey, Francisco.  Back in 2021/2022 we started working on the very intriguing question at the time of could we actually understand better genomic sequences with the emerging technologies of NLP, natural language processing.  And you have to put this in context, this was before even the word ‘generative AI' was coined, this was before ChatGPT, but we had sort of like an intuition that there was a lot of value in deploying this technology.  And so my team, sort of like a team of passionate experts in research and engineering of AI, we tackled this problem and started working on it and the result of this work was our nucleotide transformer model which we have open sourced today; it's one of the most downloaded, most popular models in genomics.  And what's interesting is we observed that simply using the technologies of what we call ‘self-supervised learning' or ‘unsupervised learning' could actually help us unlock a lot of patterns. As we know, most of genomics information is poorly understood and this is a way actually, with using the AI tool, to get some sense of the structure that's there. So how do we do this?  We basically mask a few aspects of the sequence and we ask the system to figure them out.  And so this is exactly how you teach a system to learn English, you know, you are teaching it to understand the language of genomics, and, incredibly, this approach when done at scale - and we train a lot on the NVIDIA Cambridge-1 supercomputer – allows you to have results and performances that are matching multiple specialised models.  So until then genomics and use of machine learning for genomics was for a particular task, I would have developed a specific model using mostly supervised learning, which is, I am showing you a few examples, and then channelled these examples and tried to match that, and so essentially you had one model per task.  What's really revolutionary in this new paradigm of AI is that you have a single model trained at very largescale, the AI starts to understand the patterns, and this means that very concretely we can work with our partners to uncover fascinating relationships that were previously poorly understood.  And so there is a wealth of potential that we are exploring together and it's a very exciting time. Francisco: What you're describing really highlights both the potential and the opportunities but also the responsibility we have with these powerful tools, its power, and this brings up some important ethical considerations.  And we have Harry…  Harry, we have talked about ethics frameworks in research for decades but AI seems to be rewriting the rulebook.  For your work at the Ada Lovelace Institute what makes AI fundamentally different from previous technologies when it comes to ethical considerations and how does this reshape our approach to ensuring these powerful tools benefit society as a whole? Harry: So I think when you are considering these sorts of ethical questions and these sorts of ethical challenges posed by AI and genomics it really depends on the sort of deployment that you're looking at.  From the conversation we've had so far, I think what's been hinted at is some of the diversity of applications that you might be using AI for within the context of genomics and healthcare.  So I think there's obviously big advances that have been alluded to in things like drug discovery, in things like cancer and cancer diagnosis, also these advances around gene editing, all of which have been on steroids, by artificial intelligence and particularly machine learning and deep learning. The area that we have been looking at at the Ada Lovelace Institute, and this was a project that we were doing in collaboration with the NCOB, the Nuffield Council on Bioethics, was looking at what we were calling ‘AI-powered genomic health prediction', which is very related to a technique called ‘polygenic scoring', for those who might be interested.  And that's looking at the emerging ability to make predictions about people's future health on the basis of their DNA, and it was thinking about what that ability might mean for UK society and also for how we are thinking about and delivering healthcare in the UK. Now, thinking about what the ethical challenges might be for that, I think you need to think about what specifically AI is bringing to that technique, so what it's bringing to genomic health prediction.  I think with some of the other deployments, the list of things that AI is bringing is quite similar, so it's helping with data collection and processing, so speeding up and automating data collection and preparation processes that otherwise are quite slow and very labour-intensive.  AI's also helping with the analysis of genomic and phenotype data, so helping us to understand the associations between different genomic variations and between observable traits, and this is something which without AI can often be prohibitively complex to do, and it's also sometimes suggested that on the deployment end AI can be a tool that can help us use genomic insight in healthcare more widely.  So one example of this might be using an AI chat bot to explain to a patient the results of a genomic test.  That's something that's only been mooted and I don't think there are current examples of that at the moment but that's one of the downstream applications of AI in the context of genomics. So in terms of what AI's actually doing and what it's bringing, it's really just making possible things that we've been trying to do in genomics for some time, making these things easier and cheaper and in some cases viable.  So really it's best to see it as an accelerant for genomic science; it doesn't present any brand-new ethical problems, instead what it's doing is taking some fairly old ethical challenges and making these things far more urgent.  So in terms of what those problems actually are, some of the big ones will be around privacy and surveillance, genomic health predictions produce a lot of intimate sensitive data about people and generating those insights requires the collection and the storage and the processing of a lot of very sensitive data as well.  We also have issues related to privacy around genomic discrimination, so this is the worry that people will be treated differently and in some cases unfairly on the basis of health predictions made about them.  And one of the really typical examples here is the worry that people might face higher insurance costs if they're found through genomic testing to be more likely to develop particular diseases over their life course. And then you also have a bunch of issues and questions which are more structural, so these are questions about how the availability of this kind of insight into people's future health might change or put pressure on existing ways of thinking about health and thinking about healthcare and some extreme cases thinking about the social contract.  So these are questions like does the viability of genomic health prediction lead to a radically more preventative approach to healthcare and what might this mean for what the state demands of you as a user of healthcare and as a recipient of that.  And there are also some important questions about the practicalities of delivering genomic medicine in the NHS, so questions like how does the NHS retain control and sovereignty over genomic analysis and data capacities, how do we test their efficacy at a public health level, and also – and this is something that we might talk about a bit later – what's the best deployment model for these capacities.  So that's some of the ethical and I think policy challenges that we need to be dealing with in this space. Francisco: Thank you, Harry.  And those principles you have outlined provide a solid foundation for discussing different types of applications. [Music plays] Let's talk about the InstaDeep and Genomics England partnership that is investigating the application of InstaDeep's powerful foundation model, the nucleotide transformer, and other cutting edge techniques to address several challenges in cancer research.  I have the privilege of working closely with this partnership and the potential here is immense.  Karim, could you break down for our listeners what you are working on together and what innovations you are aiming for? Karim: Absolutely, Francisco.  Actually, we are very excited by the collaboration with Genomics England.  Genomics England not only has one of the best data assets in the world when it comes to genomics, like a very well curated dataset but also a wealth of expertise on these topics, and on my side the InstaDeep team brings fundamental knowhow of machine learning models but also, as you mentioned, like powerful developed models already, such as our nucleotide transformer and others.  The culture of InstaDeep has always been to build AI that benefits everyone – this is literally in our mission – and so in particular, specifically on like current topics, really like the goal is to try to identify partners between genomic sequences of patients and the particular phenotypes or approaches.  And one of the key projects, which I mentioned that, is the one of cancer of unknown primary origin.  So when you have situations where you are not sure where a particular cancer emerged from it is critical to be able to extract this information to have the best potential care, and this is actually something where understanding of genomic sequences can bring this capability.  And so we've been getting some successful results in the collaboration but in many ways this is just the beginning.  What we are seeing is a great wealth of possibilities linking genotypes, so the information which is on the sequences themselves, the genomic sequences, and phenotypes, like the particular state of the patient, and the fact that the Genomics England team has those joint datasets creates incredible opportunities.  So we are looking at this really like identifying together what are the most useful ‘low-hanging fruits', if you want, in terms of like potentially improving a patient's care and moving forward from that. Francisco: And this collaborative approach you are describing raises questions about accelerating innovation in general.  When two organisations like Genomics England and InstaDeep come together it's like a multiplier effect in terms of expertise, data, and other resources.  Could you both share how this partnership is accelerating discoveries that might have taken years? Rich: Yeah, I mean, I think this…  Francisco, you frame it really nicely because this is what makes it so exciting to be in our position at Genomics England because what we do is we bring the particular understanding and expertise, digital infrastructure and custodianship of the National Genomic Research Library together, but actually the key is bringing the potential of genomic healthcare to everyone.  We can only do that by working in partnership, we bring our expertise and those capabilities.  And, as you say, it's about finding it in different ways, in different collaborations, that multiplier effect, and it's really exciting.  And I think the phase we're in at the moment in terms of the use of AI in genomics is we're still really early in that learning curve.  And so, as you've heard already through what Karim and I have said and also what Harry has said, there are multiple different aspects that we need to look at together, bringing different angles and understandings, and we see ourselves…  We often describe ourselves as a ‘data and evidence engine', that final word ‘evidence' is really important and it comes in the round.  So Harry really eloquently talked about a number of different considerations from an ethical perspective that need to be there.  What we need if we're going to move genomics forwards in terms of its potential to make a difference for people's lives, we need evidence around clinical efficacy of different approaches, that's absolutely a given and everyone always jumps at…  so it's almost first in line.  We need understanding about the health economics, you know, how much difference does it make for a particular investment, is it worth that investment.  Critically, it also is founded on, you know, how you might use this technology in different ways, how you use it in clinical pathways, you know, is it something that actually is addressing the particular questions which really hold back the delivery of better care.  Also in that evidence piece is an understanding of patients' and participants' expectations on how their data might be used, their expectations on privacy, the expectations that we have on understanding how equitable the use of a particular approach might be, or at least our understanding of how confident we are about the equity of the impact, and it's bringing together those different perspectives.  And that's one of the things that helps us construct the team at Genomics England so we have the expertise to help others access the data in the National Genomic Research Library for purposes our participants support but also help generate that sort of rounded package of evidence that will end up moving the dial.  So that it's not just about proving a cool widget, because that's great on its own, what drives Karim and the team is to make a difference in terms of outcomes, and that's exactly what drives us and our participants too. Francisco: And this and other partnership approaches brings up important questions about responsible innovation, and this naturally leads us to the next question for Harry, how do we harness these powerful tools when protecting our communities? Harry: Yeah, so if we are thinking about over-surveillance and the ways that vulnerable groups might be affected by the use of genomics and healthcare, I think we're talking about at least two different things here.  So one problems around the representativeness of data is it does lead to issues which you could classify as issues of differential accuracy.  So in the context of genomic prediction what you have is genomic predictive tools being more accurate for white Europeans and those with white European ancestry compared to other population groups.  And this is a product of the fact that genomic datasets and genomic predictions, the terminologies don't port well between different populations, which means if you train a genomic predictive tool on a bunch of people with white European ancestry the predictions you might make using that tool for other groups won't be as accurate as for the white Europeans.  And this can be actively harmful and dangerous for those in underrepresented groups because you are making predictions about people which just won't have the accuracy that you would expect in the context that you were deploying it. And I already mentioned this a bit in my previous answer, you have worries about discrimination, and there are a few different things here.  So with some historically marginalised groups and marginalised groups now there are longstanding historical sensitivities about being experimented on, about particular fears about eugenics and about being categorised in particular ways.  And it's worth saying here that there is obviously a racial dimension to this worry but I think there's also a class dimension, by which I mean you're far more vulnerable to being categorised unfavourably if you're poor or if you don't have a particular kind of status within society.  There is also within discrimination the idea that genomics might be used to explain away differences between different groups which in fact have a political or an economic basis.  So one example of this was during the COVID-19 pandemic, there were attempts by some commentators to explain away the fact that non-white communities had worse rates of mortality from COVID to try and attribute a genetic or a genomic basis to those differences rather than looking at some of the socioeconomic factors behind that.  So those are some worries as well. Now, when it comes to protecting particular groups I think there are a few things that can be done fairly straightforwardly.  So, one is work to improve the diversity and the representativeness of datasets.  Obviously, that's easier said than done, though it's a very clear thing that we can aspire towards and there is good work, I'm aware, that is going on in this space, some of which is being spearheaded by Genomics England, amongst other groups.  Another is just being very careful about how the results of population level genomic studies are communicated to avoid giving that impression of explaining away differences between different groups simply as things determined by genomics about which we can do nothing rather than things which have historical or socioeconomic bases.  But I also think the broader lesson is that some of these harms and these forms of discrimination are things that could theoretically affect anyone; they're not just limited to affecting marginalised groups. Genomic health predicting can produce bases for all of us to be discriminated against, things that have nothing to do with our race, our class, our sex or any other protected characteristic.  So I think there has to be thinking about how we establish or sure up more universal protections against genomic discrimination.  One thing that we can do here is simply stronger data protection law, and one of the things that we talk about in some of our reports is that how data protection law as it stands could do with being less ambiguous when it comes to how it treats genomic data and phenotype data produced as a result of genomic analysis. [Music plays] Francisco: Harry, you are in a unique position at the Ada Lovelace Institute where you bridge this gap between AI developers, researchers, policymakers and the public.  Your recent report on AI in genomics with the Nuffield Council on Bioethics offers an important blueprint for responsible AI innovation in general, so based on this cross-sector perspective, what guiding principles do we need to embrace as we navigate this intersection of AI and genomics? Harry: So I think in addition to the specific recommendations we set out in the final report of that work - which is called ‘Predicting the Future of Health' and which you can find on our website and also on the NCOB website – I think one of the biggest messages was the importance of finding a deployment model for genomic health prediction that respects that technology's strengths, what it can actually do, because there are limitations to this technology, and also which avoids circumstances in which the associated risks are difficult to deal with.  So another way of putting this is that we need a deployment model that, as well as making sure that we're ready to cope with the risks of genomic health prediction, the things like law, regulation and governance also proactively tries to design out some of those risks and finds ways of deploying this technology such that those risks don't present themselves in either as extreme a manner or don't present themselves in ways which makes them difficult to deal with. So one question that we posed in our research was whether some ways of integrating genomic health prediction may present more challenges regarding privacy, discrimination and then these other challenges that we'd identified around dependency and fragility and others. And having looked at some of the different broad approaches to using genomic health prediction within the NHS and within the UK's health system, we found that one presented by far fewest of the risks identified above, while still presenting some of the most certain benefits of genomic health prediction.  And this was using it really primarily as a targeted diagnostic tool - and this is a vision in which the NHS uses genomic health prediction quite sparingly in the first instance - and in situations to improve treatment and outcomes for those who are seriously ill or who have been identified as needing to take particular precautions regarding their health.  We think the more situational vision has a few advantages.  So one, is it allows patient and people using the health service to retain greater control over data.  We think that can also have a positive knock-on effect for worries about discrimination.  And here what you have is the absence of those pressures to share your data.  It means that it's easier for you as the user of the healthcare system to resist genomic discrimination simply by keeping your data private.  And there are some cases where that option… it shouldn't be the only option but where that option is really important. And then also one of the features of this vision is that the smaller scale of the use of genomic health prediction, presumed, can make outsourcing to third parties, which the NHS is probably likely to need to do in some cases.  It's also a vision, I think, that overall allows you to capture some of the more certain benefits to genomic health prediction which are about improvements to accuracy in predictions about people's future health at the margin, and therefore this is a deployment of this technology which is deploying it principally to people who will benefit and we know will benefit from marginal improvements in accuracy to predictions made about their future health rather than wanting to deploy those marginal improvements to the vast majority of the population where the benefit is less certain.  So this is a vision we hope sets out a way of getting some of the more certain benefits of this technology while minimising some of those broader more systemic risks. Francisco: Thank you, Harry.  Karim? Karim: Totally agree with Harry about the need for smart regulation in the field so that we make sure we have good uses of the technology but avoid the potential pitfalls.  I wanted to emphasise two points which I believe are important.  First, we are really in a fast-moving situation when we look at like AI progress.  We have seen incredible improvements over the last ten years and in particular what we call ‘artificial general intelligence', which is essentially systems that are matching human cognitive abilities, are now around the corner.  This might sound surprising but literally the last obstacles to reach AGI are being solved right now, and this means that in the next 12-24 months you will have systems that are incredibly capable.  So this emphasises the need for the type of measures and type of smart approach that Harry has described.  And I would say when you look at the intersection of AI and genomics this is a particularly important one and why it's the case, because so far in genomics our obstacle has not been data, it has been interpretation of a flood of data.  The progress that AI is making, like I just described now, means that very soon extraordinary capabilities will be available to improve patients' outcomes.  I want to inject a sense of how important is our conversation today, given what is happening, an exponential progress in AI, exponentially growing data in genomics and relatively exponential potential to build the technology for good.  But, like in other fields, we see that AI is an extremely powerful technology and we need to make sure it is used for good in fact and this is why the conversation that we have today is so important. Harry: Obviously I agree with the conclusion to all of this, is that we need to think very hard about the way that artificial intelligence and its deployment in healthcare and also just in many different walks of life is going to be affecting the way we think about public service delivery, affecting the way that we think about scientific development.  It's worth noting, though, that I think one of the biggest challenges from a policy perspective on artificial intelligence is being able to distinguish the wheat from the chaff.  There are obviously areas where AI has made huge and incredibly impressive progress over the past few years and where we reasonably expect that to continue over the next few years, but there are also areas where some of the stories being told about the capabilities of future systems probably won't be matched by the reality, but there is I think a really big and very live debate about exactly what we can reasonably expect from these technologies and therefore what the deployments of them are. Francisco: Thank you.  We are approaching the end of the episode and I'd like to conclude with a couple of questions.  Genomics England has built quite an ecosystem of industry partnerships, how do collaborations like the one with InstaDeep fit into your broader mission for the company? Rich: So linking this to the conversation that we've just been having, which is AI is making a real difference in terms of technologies that we can test, we can develop evidence on, and that is rightly creating excitement, I think our approach…  The expectation of our participants is that our role is to sit there and help people develop evidence and you can make judgments on policy based on those and that is what will drive adoption.  I think the thing that really excites me for the UK, most particularly in genomics, is our ability to be the place in the world where you can come with a new technology, whether it's genomic sequencing technology, whether it's a genomic AI approach to train that to develop evidence on its efficacy, and, if it's proven to be effective to be worth the bang for the buck to perform to the expectations that patients, the public, would have of it in terms of equity and so forth also to deploy it.  I think there is a real reason for excitement around that and it's a real opportunity that the government has highlighted and that we absolutely buy into that the UK can be the best place to do that for academics and for industry.  And our participants see real opportunity and are eager for that work to be done so that we have the evidence on which to decide what should be deployed and where.  We see opportunities in all sorts of different areas, so certainly in terms of drug discovery and all the way through to simplifying tasks which at the moment just limit the rate at which the existing uses of genomics in healthcare can happen. So I think there's opportunities across the whole length, if you like, the sort of end to end, and the breadth of opportunity, and industry, companies like InstaDeep and others that we work with, are really crucial to that.  And what we do is think about the digital infrastructure we need to, you know, have those teams able to interact with within the National Genomic Research Library carrying out their approved research projects.  Also what support they need, and that comes in different shapes and sizes, depending on the ask and also the company.  So sometimes sort of leaning in more, particularly at the start of programmes, to help people shape the question, working with our participants, thinking about the wider evidence that you might need, for example, those sort of things that Harry's touched on, but also thinking about what hands-on support companies need, because not every company is anywhere close to Karim and InstaDeep's expertise.  Sometimes this is also about supporting people to have some of those tools that they don't have or some of the knowhow that's very specific to areas of genomics, so it's absolutely crucial to it.  And I think that point of the UK being the place to come and develop that evidence in its full breadth so that policy decisions can be made not based on hype but on evidence in the round, on what will make a difference. Francisco: And, Karim, looking ahead, also in retrospect, what have been your key learnings about making this cross-sector partnership work? Karim: We live in an extraordinary time and I want to emphasise the potential of scientific discovery in the next two or three years.  AI is going to move from, let's say, digital style, you know, technologies like coding and maths towards more like science and biology.  In particular, genomics is going to be a fascinating area in terms of potential, and I agree with Rich and Harry, it's all in the end about proving on the ground the potential of those capabilities.  And at InstaDeep we are passionate about the tech – I think you might have felt that – but we're also passionate about the applications.  The best results come when you bring expertise from multiple domains; machine learning and AI experts will require the expertise of genomic experts, biologists, healthcare practitioners, to be able to translate the potential of those technologies in concrete outcomes.  And we've seen this on multiple successful projects we've done with Genomics England but really this suggests that we are going to have in the next 3-5 years way more progress than we had in the last five and really my wish is that collectively we seize this opportunity and we do it in a responsible and thoughtful manner. [Music plays] Francisco: We'll wrap up there.  Thank you to our guests, Karim Beguir, Harry Farmer and Rich Scott, for joining me today as we discuss the role of AI in genomics research.  If you wish to hear more like this, please subscribe to Behind the Genes on your favourite podcast app.  Thank you for listening.  I have been your host, Francisco Azuaje.  This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand. [Music plays]    

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

John and Jonathan tackle the dark side of IVF and surrogacy, from terrifying abuse cases to legal highways that allow registered sex offenders to become parents. They connect these issues to the pro-life movement and discuss the Trump administration's surprising stance on IVF.

As the lead wreaks havoc on Cooper's development, Shannon searches for answers. Desperate to get a handle on what was happening to her son, she grabs onto a lifeboat - nursing school. Andy tries to piece together the past to make sense of the present.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper BurkettEP2 features Keith Nobbs and Frank Wood. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

America Out Loud PULSE with Dr. Randall Bock – Public health is no longer about care—it's about control. From genetically engineered ticks to coerced vaccination, the system bypasses informed consent in the name of the “greater good.” Covert coercion, legal threats, and weaponized bioethics erode autonomy. I expose how this machinery operates and why resisting its encroachment on personal sovereignty is no longer optional...

America Out Loud PULSE with Dr. Randall Bock – Public health is no longer about care—it's about control. From genetically engineered ticks to coerced vaccination, the system bypasses informed consent in the name of the “greater good.” Covert coercion, legal threats, and weaponized bioethics erode autonomy. I expose how this machinery operates and why resisting its encroachment on personal sovereignty is no longer optional...

Moral philosopher Travis Rieder joins "Values & Interests" to explore how we might pursue ethical lives in an era of global crisis. From climate change and violent conflict to the dilemmas of daily life, Rieder argues that we must radically overhaul our outdated moral toolkits to face the challenges of an increasingly contradictory and catastrophic world. Dr. Travis Rieder is an associate research professor at the Berman Institute of Bioethics at Johns Hopkins University. His latest book is "Catastrophe Ethics: How to Choose Well in a World of Tough Choices." For more, please go to: https://carnegiecouncil.co/values-interests-rieder

A mysterious dust fills a young family's apartment. The truth begins to unravel when the mother gets a call from the pediatrician - the monster deep within the walls has been unleashed. LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett. EP1 features Zak Orth, Jenny Maguire, Daphne Gaines, and Micheal Gaston. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In his second time on the Them Before Us podcast, Professor Robert P. George shared about his new book: "Seeking Truth & Speaking Truth: Law and Morality in our Cultural Moment." In his decades as a professor, George has taught between 8,000-10,000 students in the Ivy Leagues and hopes this resource will shift our culture back to reason and truth seeking instead of emotionalism.Buy the book: https://www.amazon.com/Thinking-Things-Through-Morality-Culture/dp/1641774215Check out Episode #019, where Professor George lays out "natural law" and why it matters for children: https://open.spotify.com/episode/06Gx9TRXzF2De8sLlXLOUM?si=6kON-jD-SJ2EcW2d4sRcdQ&nd=1&dlsi=7ce62b7944e746f1Bio: Robert P. George is McCormick Professor of Jurisprudence and Director of the James Madison Program in American Ideals and Institutions. He has served as chairman of the United States Commission on International Religious Freedom (USCIRF), and before that on the President's Council on Bioethics and as a presidential appointee to the United States Commission on Civil Rights. He has also served as the U.S. member of UNESCO's World Commission on the Ethics of Scientific Knowledge and Technology (COMEST). He is a former Judicial Fellow at the Supreme Court of the United States, where he received the Justice Tom C. Clark Award. A graduate of Swarthmore College, he holds J.D. and M.T.S. degrees from Harvard University and the degrees of D.Phil., B.C.L., D.C.L., and D.Litt. from Oxford University. He has been a visiting professor at Harvard Law School and is a member of the American Academy of Sciences and Letters and the Council on Foreign Relations.

Where do ethics and palliative care overlap, and is there really no harm in doing both? Exercise your autonomy by choosing to listen to this episode, in which your beneficent hosts, Sarah and Dan, get ethical with Phoebe Winn and Bob Macauley, both palliative care physicians whose careers have also brought them to the realm of questions that sometimes just don't have answers. Thankfully, our expert guests are here to help us all understand. I mean, it would hardly be worth listening to if it were just us, right?Phoebe Winn's recommended ethics readings (click the PMID's for links):Diekema DS. Parental refusals of medical treatment: the harm principle as threshold for state intervention. Theor Med Bioeth. 2004;25(4):243-64. doi: 10.1007/s11017-004-3146-6. PMID: 15637945. Kon AA. Informed non-dissent: a better option than slow codes when families cannot bear to say "let her die". Am J Bioeth. 2011 Nov;11(11):22-3. doi: 10.1080/15265161.2011.603796. PMID: 22047119.Mercurio MR, Cummings CL. Critical decision-making in neonatology and pediatrics: the I-P-O framework. J Perinatol. 2021 Jan;41(1):173-178. doi: 10.1038/s41372-020-00841-6. Epub 2020 Sep 30. PMID: 32999448.Diekema DS. Adolescent Brain Development and Medical Decision-making. Pediatrics. 2020 Aug;146(Suppl 1):S18-S24. doi: 10.1542/peds.2020-0818F. PMID: 32737228.Diekema DS, Botkin JR; Committee on Bioethics. Clinical report--Forgoing medically provided nutrition and hydration in children. Pediatrics. 2009 Aug;124(2):813-22. doi: 10.1542/peds.2009-1299. Epub 2009 Jul 27. PMID: 19651596.Taub S, Macauley R; COMMITTEE ON BIOETHICS. Responding to Parental Requests for Nondisclosure to Patients of Diagnostic and Prognostic Information in the Setting of Serious Disease. Pediatrics. 2023 Oct 1;152(4):e2023063754. doi: 10.1542/peds.2023-063754. PMID: 37743818.Really all the AAP Bioethics Guidelines are helpful to know about: https://publications.aap.org/pediatrics/collection/528/Committee-on-BioethicsAnd, in case you missed it in Episode 40, Bob Macauley's fabulous new book about his career in palliative care and ethics:  Because I Knew You

Lexi Silver is 15 years old. She lost both of her parents before she turned 11. That should tell you enough—but it doesn't. Because Lexi isn't here for your pity. She's not a sob story. She's not a trauma statistic. She's a writer, an advocate, and one of the most emotionally intelligent people you'll ever hear speak into a microphone.In this episode, Lexi breaks down what grief actually feels like when you're a kid and the adults around you just don't get it. She talks about losing her mom on Christmas morning, her dad nine months later, how the system let her down, and how Instagram trolls tell her she's faking it for attention. She also explains why she writes, what Experience Camps gave her, how she channels anger into poems, and what to say—and not say—to someone grieving.Her life isn't a Netflix drama. But it should be.And by the way, she's not “so strong.” She's just human. You'll never forget this conversation.RELATED LINKS• Lexi on Instagram: @meet.my.grief• Buy her book: The Girl Behind Grief's Shadow• Experience CampsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textMegan and Michelle welcome guest Mary Fusillo, of The Eggsplanation podcast, to discuss bioethics, embryo matchmaking, posthumous reproduction, D1 athletes, ovarian rejuvenation, social surrogacy, Hermes bags, and taking control of your fertility.Learn more about Mary's important work!Family Solutions InternationalThe Eggsplanation PodcastFollow The Eggsplanation on Instagram****************Want to support Prosecco Theory?Become a Patreon subscriber and earn swag!Check out our merch, available on teepublic.com!Follow/Subscribe wherever you listen!Rate, review, and tell your friends!Follow us on Instagram!****************Ever thought about starting your own podcast? From day one, Buzzsprout gave us all the tools we needed get Prosecco Theory off the ground. What are you waiting for? Follow this link to get started. Cheers!!Support the show

Pedro Moura closes out his Sunday School series on anthropology, bioethics, and genetic engineering with this third and final lesson.

Dr. Annie Friedrich joined TMC for a virtual seminar on Friday, October 11th, 2024. Dr. Friedrich is an Assistant Professor of Bioethics and Medical Humanities in the Institute for Health & Equity at the Medical College of Wisconsin. She received her PhD in Health Care Ethics from Saint Louis University with a focus on clinical ethics, pediatric ethics, and empirical research methods. She is a certified clinical ethics consultant (HEC-C) and is the co-chair of the ethics committee at Children's Wisconsin, in addition to serving on other affiliated ethics committees. She is also an ethics educator and teaches bioethics to medical students, graduate students, and other health professionals. This seminar, titled "Flourishing in the Cracks: Cultivating Moral Resilience in the Midst of Moral Distress," explores moral complexity, confusion, uncertainty, and distress as inevitable features of the healthcare system. Leaving this distress unacknowledged and unresolved can lead to frustration, lack of meaning in work, and burnout. In this presentation, Dr. Friedrich examines the moral and spiritual dimensions of wellbeing and burnout, with a particular focus on factors contributing to moral distress, and will discuss how we can build flourishing, morally resilient communities for both patients and practitioners.

A problem plagues modern healthcare: machines are setting the standard of care, and human clinicians are struggling to keep up. Artificial intelligence will only make this worse. The technical mindset fragments patient care and draws us further from shalom even as pursue surrogate markers that are meant to restore health. How can we, as Christian clinicians, respond wisely and well to this problem? One response is found in the story of the God's people in the Bible, specifically in the story of Israel's adoption into the family of God. The Theology, Medicine, and Culture Initiative (TMC) at Duke Divinity School and the Trent Center for Bioethics, Humanities & History of Medicine at Duke co-sponsored this seminar entitled "The Uncanny Valley: Remaining Human in Healthcare" on November 8, 2024 with Dr. Joshua Briscoe. Joshua Briscoe, MD is a Hospice and Palliative Care physician at the Durham VA Medical Center where he also serves on the Ethics Consultation Service. He's an assistant professor of Medicine and of Psychiatry and Behavioral Sciences at Duke University School of Medicine, and faculty associate with the Trent Center for Bioethics, Humanities and History of Medicine. He writes about issues at the intersection of medicine, technology, and moral formation in a monthly newsletter entitled Notes from a Family Meeting.

Michelle Andrews built a career inside the pharma machine long before anyone knew what “DTC” meant. She helped launch Rituxan and watched Allegra commercials teach America how to ask for pills by name. Then she landed in the cancer fun house herself, stage 4 breast cancer, and learned exactly how hollow all the “journey” slide decks feel when you're the one circling the drain.We talk about what happens when the insider becomes the customer, why pill organizers and wheat field brochures still piss her off, and how she fired doctors who couldn't handle her will to live. You'll hear about the dawn of pharma advertising, the pre-Google advocacy hustle, and what she wants every brand team to finally admit about patient experience.If you've ever wondered who decided windsurfing was the best way to sell allergy meds—or what happens when you stop caring if you make people uncomfortable—listen up.RELATED LINKSMichelle Andrews on LinkedInTrinity Life Sciences – Strategic AdvisoryJade Magazine – Ticking Time Bombs ArticleNIHCM Foundation – Breast Cancer StoryFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

I spoke with Graham Sack about Neuro-Cinema: From Synapse to Montage at Onassis ONX Summer Showcase 2025. See more context in the rough transcript below. This is a listener-supported podcast through the Voices of VR Patreon. Music: Fatality

Attorney and bioethicist Karolina Zhukoff sits down with Dr. Jonathan Moreno, Professor Emeritus at the University of Pennsylvania, to discuss his new book, “Absolutely Essential: Bioethics and the Rules-Based International Order.” They delve into the historical development of bioethics since its emergence post-World War II, focusing on the evolution of doctor-patient relationships and the significant influence of the Nuremberg Code. The conversation also covers the ways in which Dr. Moreno's upbringing inspired his work, the global impact of COVID-19 on bioethics, and the challenges posed to the international rules-based order by geopolitical shifts and emerging technologies. 00:00 Introduction 01:33 The Essence of Bioethics 04:20 Historical Context of Bioethics 08:04 Personal Influences on Dr. Moreno 11:09 Global Perspectives on Medical Ethics 21:11 Impact of COVID-19 on Bioethics 27:23 Future Challenges and Emerging Technologies 32:55 Conclusion and Final Thoughts

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pedro Moura continues his three-part Sunday School series regarding Christian views on anthropology, bioethics, and genetic engineering.

Date: July 9, 2025 Guest Skeptics: Dr. Cindy Bitter is an Associate Professor in the Division of Emergency Medicine at Saint Louis University. She has a Master's in Bioethics, and she is passionate about EM capacity building and physician resilience, especially improving wellness through time in nature.    Dr. Amy Bi is a graduate from […] The post SGEM Xtra: Career Advice from Buffy the Vampire Slayer first appeared on The Skeptics Guide to Emergency Medicine.

Science writer Heather Zieger, research analyst for The Center for Bioethics and Human Dignity, talks about her connection with those affected by the flooding in Texas.  She also explains why the flash flooding was so devastating.  She also talks about how to keep our brains healthy and even keep your brains growing. Transform Iran's Lana Silk updates us on the situation for Christians in Iran as the Islamic government is turning on its own people in the wake of their war with Israel.   Faith Radio podcasts are made possible by your support. Give now: Click here

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In today's episode, we're sitting down with Jennifer Lahl, founder of the Center for Bioethics and Culture Network, to discuss how she founded the CBC coming from her background in the medical field. We also talk about the risks of IVF to both women and babies, and the disturbing trend of professionals in the fertility industry saying that intercourse would be for fun while all babies would be born via artificial reproductive technologies. And what is the best method to persuade others to see the harm that IVF perpetuates? Share the Arrows 2025 is on October 11 in Dallas, Texas! Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠sharethearrows.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for tickets now! Sponsored by ⁠Carly Jean Los Angeles⁠, ⁠Good Ranchers⁠, and ⁠EveryLife⁠. Buy Allie's new book, "Toxic Empathy: How Progressives Exploit Christian Compassion": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://a.co/d/4COtBxy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Timecodes: (00:30) Introduction (05:20) What fueled Jennifer's work (08:00) IVF baby risks (15:45) What is natural (18:25) Egg selling exploitation (30:10) Persuading those against IVF (33:20) Embryo adoption (43:03) Contraception (45:50) Transgender "medicine" --- Today's Sponsors: Good Ranchers — Go to ⁠⁠⁠⁠⁠⁠⁠⁠https://⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GoodRanchers.com⁠⁠⁠⁠⁠⁠⁠⁠ and subscribe to any of their boxes (but preferably the Allie Beth Stuckey Box) to get free Waygu burgers, hot dogs, bacon, or chicken wings in every box for life. Plus, you'll get $40 off when you use code ALLIE at checkout. We Heart Nutrition — Get 20% off women's vitamins with We Heart Nutrition, and get your first bottle of their new supplement, Wholesome Balance; use code ALLIE at ⁠⁠⁠⁠⁠https://www.WeHeartNutrition.com⁠⁠⁠⁠⁠. Pre-Born — Will you help rescue babies' lives? Donate by calling #250 & say keyword 'BABY' or go to Preborn.com/ALLIE. Fellowship Home Loans — Fellowship Home Loans is a mortgage lending company that offers home financing solutions while integrating Christian values such as honesty, integrity, and stewardship. Go to ⁠⁠fellowshiphomeloans.com/allie⁠⁠ to get up to $500 credit towards closing costs when you finance with Fellowship Home Loans. --- Related Episodes: Ep 1171 | Egg Donation Centers Are Exploiting College Girls & Military Wives | Guest: Kallie Fell https://podcasts.apple.com/us/podcast/ep-1171-egg-donation-centers-are-exploiting-college/id1359249098?i=1000703514590 Ep 681 | Gender Identity or Sexual Fetish? & Big Win for Virginia Parents | Guest: Jennifer Lahl https://podcasts.apple.com/us/podcast/ep-681-sexual-fetish-or-transgender-big-win-for-virginia/id1359249098?i=1000580099826 Ep 1037 | The Government Doesn't Want Christians to Adopt | Guest: Josh Weigel https://podcasts.apple.com/us/podcast/ep-1037-the-government-doesnt-want-christians-to/id1359249098?i=1000663017509 Ep 927 | Is Tumblr Making Kids Trans? | Guest: Daisy Strongin (Part One) https://podcasts.apple.com/us/podcast/ep-927-is-tumblr-making-kids-trans-guest-daisy-strongin/id1359249098?i=1000640465566 Ep 928 | Losing ‘Gender Identity' & Finding My Faith | Guest: Daisy Strongin (Part Two) https://podcasts.apple.com/us/podcast/ep-928-from-transition-to-conversion-guest-daisy-strongin/id1359249098?i=1000640577375 --- Buy Allie's book, You're Not Enough (& That's Okay): Escaping the Toxic Culture of Self-Love: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://alliebethstuckey.com/book⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Relatable merchandise – use promo code 'ALLIE10' for a discount: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://shop.blazemedia.com/collections/allie-stuckey Learn more about your ad choices. Visit megaphone.fm/adchoices

Despite medicine's remarkable advances, has it actually taken a wrong turn and lost something pretty important? What is the dominant worldview of medicine and health care today and how has that affected both patients and health care providers? What are the virtues that should govern health care to get it back on track? We'll answer these questions and more with our guest, Dr. Brent Waters, emeritus professor and founding director of the Stead Center for Ethics and Values at Garrett Evangelical Seminary. Brent will be a plenary speaker at the national conference of the Center for Bioethics and Human Dignity, June 26-28. See cbhd.org/conference for more information.Guest Bio: Brent Waters is the Emeritus Jerre and Mary Joy Professor of Christian Social Ethics, and Emeritus Director of the Jerre L. and Mary Joy Stead Center for Ethics and Values at Garrett-Evangelical Theological Seminary, Evanston, Illinois. He came to Garrett in 2001 and retired in 2022.Waters is the author or co-editor of 11 books, including most recently, Common Callings and Ordinary Virtues: Christian Ethics for Everyday Life.==========Think Biblically: Conversations on Faith and Culture is a podcast from Talbot School of Theology at Biola University, which offers degrees both online and on campus in Southern California. Find all episodes of Think Biblically at: https://www.biola.edu/think-biblically. Watch video episodes at: https://bit.ly/think-biblically-video. To submit comments, ask questions, or make suggestions on issues you'd like us to cover or guests you'd like us to have on the podcast, email us at thinkbiblically@biola.edu.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if doing the most good was simpler—and more within reach—than you ever imagined? In this powerful episode of The Greatness Machine, Darius is joined by world-renowned moral philosopher Peter Singer for a conversation that will challenge how you think about ethics, generosity, and your role in making the world better. Peter, best known for his groundbreaking work “The Life You Can Save,” shares thought-provoking insights on effective altruism, the moral obligations of those living in affluence, and how small, intentional actions can create ripple effects of real change. From fighting global poverty to advocating for animal rights, Peter's work has inspired millions to rethink their impact—and today, he might just do the same for you. In this episode, Darius and Peter will discuss: (00:00) Introduction to Effective Altruism (06:11) Understanding Effective Altruism (11:57) The Life You Can Save: A Nonprofit Overview (18:05) Philanthropy and Meaning in Life (23:55) Profit for Good: Business and Altruism (24:54) Profit for Good Conference: A New Business Paradigm (30:01) The Role of Bioethics in Modern Society (37:32) Activism and Personal Motivation in Ethical Issues (38:35) Reflections on Global Issues: Past and Present (41:42) Making a Difference: Individual Impact and Career Choices (47:07) Overcoming Barriers to Greatness Peter Singer is an Australian moral philosopher known for his work in applied ethics from a utilitarian perspective. He is Emeritus Professor of Bioethics at Princeton University and author of Animal Liberation and the influential essay “Famine, Affluence, and Morality.” Singer has shifted from preference to hedonistic utilitarianism over his career. He founded Monash University's Centre for Human Bioethics, co-founded Animals Australia, and established the nonprofit The Life You Can Save. Recognized as Australian Humanist of the Year in 2004, he is considered one of Australia's most influential public intellectuals. Sponsored by: Huel: Try Huel with 15% OFF + Free Gift for New Customers today using my code greatness at https://huel.com/greatness. Fuel your best performance with Huel today! Indeed: Get a $75 sponsored job credit to boost your job's visibility at Indeed.com/DARIUS. Notion: Get Notion Mail for free right now at notion.com/machine. ShipStation: Go to shipstation.com and use code GREATNESS to sign up for your FREE trial. Shopify: Sign up for a $1/month trial period at shopify.com/darius.  Connect with Peter: Website: https://www.petersinger.info/ Website: http://thelifeyoucansave.org/  Podcast: https://podcasts.apple.com/ee/podcast/lives-well-lived/id1743702376  Connect with Darius: Website: https://therealdarius.com/ Linkedin: https://www.linkedin.com/in/dariusmirshahzadeh/ Instagram: https://www.instagram.com/imthedarius/ YouTube: https://therealdarius.com/youtube Book: The Core Value Equation https://www.amazon.com/Core-Value-Equation-Framework-Limitless/dp/1544506708 Write a review for The Greatness Machine using this link: https://ratethispodcast.com/spreadinggreatness.  Learn more about your ad choices. Visit megaphone.fm/adchoices